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Recommendations
pertaining to the use of
viral vaccines: influenza
Review of influenza activity — 2002
National Institute for Communicable Diseases
(Gauteng Area)
The 2002 influenza season was quiet with comparatively low
school absenteeism, showing only a short peak rising above
the mean absentee rate calculated over a 5-year period.
However, this was ascribed to the start of the winter school
holidays, and diarrhoeal disease.  A total of 130 isolations of
influenza virus were made from specimens sent to the
National Institute for Communicable Diseases during the
course of the year.  The majority 76 (58%) were influenza B,
49 (38%) were influenza A H1N1/H1N2, and only 5 (4%)
were influenza A H3N2.  Although isolates were made from
the middle of April to the middle of September, the bulk
(90%), were made between the middle of June and the end of
August.
Recommendations
Vaccine formulation
The following strains have been recommended by the World
Health Organisation for the 2003 Southern hemisphere
influenza season:
• A/Moscow/10/99 (H3N2)-like strain
• A/New Caledonia/20/99 (H1N1)-like strain
• B/Hong Kong/330/2001-like strain.
The actual viral strains recommended for the vaccine for
each component are as follows:
• A/Panama/2007/99 (RESVIR-17) for the A/Moscow/
10/99-like strain
• A/New Caledonia/20/99 (IVR-116) for the A/New
Caledonia/20/99-like strain
• B/Shangdong/7/97 (or B/Brisbane/32/2002) for the
B/Hong Kong/330/2001-like strain
Vaccines should contain 15 µg of each haemagglutinin
antigen in each 0.5 ml dose.
Indications
• Persons (adults or children) who are at high risk for
influenza and its complications because of underlying
medical conditions and who are receiving regular medical
care for conditions such as chronic pulmonary and cardiac
disease, chronic renal diseases, diabetes mellitus and
similar metabolic disorders, and individuals who are
immunosuppressed (including HIV-infected persons with
CD4 counts above 200/ml).
• Residents of old-age homes, chronic care and
rehabilitation institutions.
• Children on long-term aspirin therapy.
• Medical and nursing staff responsible for the care of high-
risk cases.
• Adults and children who are family contacts of high-risk
cases.
• All persons over the age of 65 years.
• Women who would be in the second or third trimester of
pregnancy during the influenza season.  Pregnant women
with medical conditions placing them at risk for influenza
complications should be immunised at any stage of
pregnancy.
• Any persons wishing to protect themselves from the risk
of contracting influenza, especially in industrial settings,
where large-scale absenteeism could cause significant
economic losses.
Dosage
Adults: Whole or split-product or subunit vaccine:1 dose IM 
Children (< 12 years) Split-product or subunit vaccine: 1 dose
IM 
Children < 9 years who have never been vaccinated should
receive 2 doses 1 month apart
Children < 3 years of age should receive half the adult dose
on two occasions separated 1 month apart
Contraindications
• Persons with a history of severe hypersensitivity to eggs.
• Persons with acute febrile illnesses should preferably be
immunised after symptoms have disappeared.
• The vaccine should be avoided in the first trimester of
pregnancy unless there are specific medical indications -
see above indication No. 7.
Timing
Vaccines should be given sufficiently early to provide
protection for the winter. A protective antibody response
takes about 2 weeks to develop.
Chemoprophylaxis
In cases where vaccine has not been administered,
consideration should be given to the use of supplementary
chemoprophylaxis with amantadine in certain high-risk
individuals, e.g. patients with chronic lung and heart
diseases.  Amantadine should be administered in a dosage of
200 mg daily in 2 divided doses for the duration of the
epidemic activity, i.e. approximately 6 - 12 weeks.  The dosage
should be reduced in persons with renal disease and persons
over the age of 65 years.
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